MDACC Study No:2012-0984 ( NCT No: NCT01660906)
Title:A Phase IV, Open-Label, Multicenter Study of Dasatinib in Chronic-Phase Chronic Myeloid Leukemia (CP-CML) Patients with Chronic Low-Grade Non-Hematologic Toxicity to Imatinib
Principal Investigator:Jorge Cortes
Treatment Agent:Dasatinib
Study Status:Terminated
Study Description:The goal of this clinical research study is to learn if switching to dasatinib
from imatinib can help to improve the side effects that you had while receiving
imatinib. The safety of this drug will also be studied.

Dasatinib is designed to block certain proteins from causing cancer cells to
grow out of control. This may cause the cancer cells to die.
Hide details for General InformationGeneral Information

Disease Group:Leukemia
Phase of Study:Phase IV
Treatment Agents:Dasatinib
Treatment Location:Both at MDACC & and Other Sites
Estimated Length of Stay in Houston:
Supported By:Bristol-Myers Squibb Research and Development
Return Visit:
Home Care:

Hide details for Study Contact InformationStudy Contact Information

Physician Name:Jorge Cortes
For Clinical Trial Enrollment:713-794-5783
For General Questions about Clinical Trials:1-877-MDA-6789

Show details for Study Objectives / OutcomesStudy Objectives / Outcomes
Show details for Study Status InformationStudy Status Information
Show details for Enrollment EligibilityEnrollment Eligibility
Show details for Resources and LinksResources and Links
Show details for ResultsResults